DAVIS, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI), (Nasdaq:MBII), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, today announced that it has relocated its corporate headquarters to 1540 Drew Avenue, Davis, CA 95618, effective December 8, 2014.
The new office and laboratory spaces are approximately 45,000 square feet and will house all of the Company's corporate functions as well as research and development. The laboratory space is designed to create a collaborative and productive work environment and to enhance safety. With expanded facilities in fermentation, formulation, and greenhouses, this new space is intended to support MBI's commitment to discovering and developing effective and environmentally responsible bio-based products that promote plant health and control unwanted pests in agriculture and water treatment markets.
The Company's business numbers remain the same: Tel: 1.530.750.2800 / Fax: 1.530.750.2808
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (Nasdaq:MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.
Forward Looking Statements
Portions of this press release may constitute "forward-looking statements," and assumptions underlying such forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any such forward-looking statements are made within the "safe-harbor" protections of the PSLRA, should not be relied upon as representing our views as of any subsequent date, and we are under no obligation to, and expressly disclaims any responsibility to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements in this filing include those regarding: the anticipated filing date of the Company's Form 10-Q and the Company's expectations regarding regaining full compliance with NASDAQ continued listing requirements. Such forward-looking statements are based on information available to us as of the date of this release and involve a number of risks and uncertainties, some beyond our control, that could cause actual results to differ materially from those anticipated by these forward-looking statements. Such risks include the uncertainty surrounding the timing and results of the Audit Committee's independent investigation of accounting matters, the potential need for restatement of our prior period financial statements, how promptly the investigation of accounting matters can be completed and any results thereof can be resolved, and potential legal or regulatory action related to the matters under investigation. In addition, the Company faces other risks and uncertainties that could affect its ability to complete the filing of its Form 10-Q and to regain compliance with the NASDAQ listing requirements. Additional information that could lead to material changes in our performance is contained in our filings with the Securities and Exchange Commission.
CONTACT: Media Contact: Cory Ziskind ICR 646-277-1232 Cory.Ziskind@icrinc.com
Source:Marrone Bio Innovations